THOMAS MONATH to Yellow Fever
This is a "connection" page, showing publications THOMAS MONATH has written about Yellow Fever.
Connection Strength
9.192
-
Responding to the threat of urban yellow fever outbreaks. Lancet Infect Dis. 2017 03; 17(3):248-250.
Score: 0.524
-
Yellow Fever Remains a Potential Threat to Public Health. Vector Borne Zoonotic Dis. 2016 08; 16(8):566-7.
Score: 0.508
-
Yellow fever. J Clin Virol. 2015 Mar; 64:160-73.
Score: 0.451
-
Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012 Apr; 11(4):427-48.
Score: 0.377
-
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011 Aug 11; 29(35):6008-16.
Score: 0.358
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.352
-
Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine. 2010 May 14; 28(22):3827-40.
Score: 0.328
-
Yellow fever recommendations for tourists to Kenya: a flawed risk assessment. J Travel Med. 2009 Mar-Apr; 16(2):146; author reply 146-7.
Score: 0.305
-
Yellow fever: 100 years of discovery. JAMA. 2008 Aug 27; 300(8):960-2.
Score: 0.294
-
Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med. 2007 Nov 29; 357(22):2222-5.
Score: 0.279
-
Treatment of yellow fever. Antiviral Res. 2008 Apr; 78(1):116-24.
Score: 0.279
-
Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot. 2006 Dec; 99(5):341-7.
Score: 0.261
-
New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis. 2005 Oct; 18(5):387-94.
Score: 0.241
-
Yellow fever vaccine. Expert Rev Vaccines. 2005 Aug; 4(4):553-74.
Score: 0.238
-
Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005 Feb; 72(2):189-97.
Score: 0.230
-
Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg. 2004 Nov; 71(5):639-45.
Score: 0.226
-
Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil. Microbiol Spectr. 2024 May 02; 12(5):e0370323.
Score: 0.216
-
Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever. Clin Infect Dis. 2023 08 22; 77(4):565-573.
Score: 0.208
-
Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients. Clin Immunol. 2023 06; 251:109321.
Score: 0.202
-
Pathogenesis and pathophysiology of yellow fever. Adv Virus Res. 2003; 60:343-95.
Score: 0.199
-
Epidemiology and ecology of yellow fever virus. Adv Virus Res. 2003; 61:291-315.
Score: 0.199
-
Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002 Nov 08; 51(RR-17):1-11; quiz CE1-4.
Score: 0.197
-
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
Score: 0.190
-
Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002 May 15; 34(10):1369-78.
Score: 0.190
-
Yellow fever: an update. Lancet Infect Dis. 2001 Aug; 1(1):11-20.
Score: 0.180
-
Facing up to re-emergence of urban yellow fever. Lancet. 1999 May 08; 353(9164):1541.
Score: 0.154
-
Does restricted distribution limit access and coverage of yellow fever vaccine in the United States? Emerg Infect Dis. 1998 Oct-Dec; 4(4):698-702.
Score: 0.148
-
Yellow fever vaccine supply: a possible solution. Lancet. 2016 Apr 16; 387(10028):1599-600.
Score: 0.125
-
Fever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virus. Infect Genet Evol. 2013 Oct; 19:292-311.
Score: 0.101
-
Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg. 1993 Feb; 48(2):274-99.
Score: 0.100
-
The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011 Aug; 11(8):622-32.
Score: 0.090
-
Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg. 1991 Jul; 45(1):1-43.
Score: 0.090
-
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine. 2009 Oct 09; 27(43):5974-81.
Score: 0.079
-
Type B hepatitis and yellow fever infections in West Africa. Trans R Soc Trop Med Hyg. 1987; 81(1):172-3.
Score: 0.066
-
Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984. Bull World Health Organ. 1987; 65(6):855-60.
Score: 0.066
-
Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis. 1987 Jan-Feb; 9(1):165-75.
Score: 0.066
-
17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007 Apr 12; 25(15):2758-65.
Score: 0.066
-
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol. 1986 Dec; 60(3):1153-5.
Score: 0.065
-
Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. J Clin Microbiol. 1986 Jan; 23(1):129-34.
Score: 0.061
-
Glad tidings from yellow fever research. Science. 1985 Aug 23; 229(4715):734-5.
Score: 0.060
-
A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol. 2004 Sep; 78(18):9998-10008.
Score: 0.056
-
Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004 May; 78(9):4761-75.
Score: 0.054
-
Detection of yellow fever virus in serum by enzyme immunoassay. Am J Trop Med Hyg. 1984 Jan; 33(1):151-7.
Score: 0.053
-
Traditional and novel approaches to flavivirus vaccines. Int J Parasitol. 2003 May; 33(5-6):567-82.
Score: 0.051
-
Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines. J Virol. 2002 Feb; 76(4):1932-43.
Score: 0.047
-
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology. 2001 Nov 25; 290(2):309-19.
Score: 0.046
-
Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg. 1981 Mar; 30(2):431-43.
Score: 0.044
-
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
Score: 0.043
-
Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans R Soc Trop Med Hyg. 1981; 75(2):282-6.
Score: 0.043
-
Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg. 1980 Sep; 29(5):912-28.
Score: 0.042
-
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas. Am J Trop Med Hyg. 1980 Jul; 29(4):624-34.
Score: 0.042
-
Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hosts. Trans R Soc Trop Med Hyg. 1974; 68(1):30-8.
Score: 0.027
-
Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg. 1993 May-Jun; 87(3):337-9.
Score: 0.025
-
Importance of nonhuman primates in yellow fever epidemiology in Nigeria. Trop Geogr Med. 1973 Mar; 25(1):28-38.
Score: 0.025
-
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observations. Bull World Health Organ. 1973; 49(2):113-21.
Score: 0.025
-
The 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemic. Bull World Health Organ. 1973; 49(2):123-8.
Score: 0.025
-
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ. 1973; 49(3):235-44.
Score: 0.025
-
Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol. 1989 Dec; 40(4):396-9.
Score: 0.020
-
Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg. 1989 May-Jun; 83(3):401-6.
Score: 0.019
-
Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg. 1988 May; 38(3):647-50.
Score: 0.018
-
Epidemic yellow fever in eastern Nigeria, 1986. Lancet. 1988 Mar 19; 1(8586):630-3.
Score: 0.018
-
Aedes albopictus, an exotic mosquito vector in the United States. Ann Intern Med. 1986 Sep; 105(3):449-51.
Score: 0.016
-
The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinations. Bull World Health Organ. 1984; 62(4):585-90.
Score: 0.013
-
[Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):31-43.
Score: 0.011
-
[Yellow fever in Senegal from 1976 to 1980 (author's transl)]. Med Trop (Mars). 1981 Jan-Feb; 41(1):45-51.
Score: 0.011
-
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981; 59(6):895-900.
Score: 0.011
-
Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations. Am J Trop Med Hyg. 1980 Sep; 29(5):929-40.
Score: 0.011
-
Arbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. II. Entomological investigations and viruses isolated. Trans R Soc Trop Med Hyg. 1974; 68(1):39-43.
Score: 0.007